RU2626540C2 - Способы обнаружения патологических изменений в органе или системе органов - Google Patents
Способы обнаружения патологических изменений в органе или системе органов Download PDFInfo
- Publication number
- RU2626540C2 RU2626540C2 RU2013146856A RU2013146856A RU2626540C2 RU 2626540 C2 RU2626540 C2 RU 2626540C2 RU 2013146856 A RU2013146856 A RU 2013146856A RU 2013146856 A RU2013146856 A RU 2013146856A RU 2626540 C2 RU2626540 C2 RU 2626540C2
- Authority
- RU
- Russia
- Prior art keywords
- mir
- mirna
- microrna
- normalizing
- mirnas
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 207
- 238000000034 method Methods 0.000 title claims abstract description 202
- 238000001514 detection method Methods 0.000 title abstract description 33
- 231100000915 pathological change Toxicity 0.000 title abstract description 7
- 230000036285 pathological change Effects 0.000 title abstract description 7
- 239000002679 microRNA Substances 0.000 claims abstract description 768
- 108700011259 MicroRNAs Proteins 0.000 claims abstract description 257
- 230000007170 pathology Effects 0.000 claims abstract description 174
- 239000013060 biological fluid Substances 0.000 claims abstract description 110
- 210000004789 organ system Anatomy 0.000 claims abstract description 104
- 238000012360 testing method Methods 0.000 claims abstract description 100
- 150000001875 compounds Chemical class 0.000 claims abstract description 36
- 230000007613 environmental effect Effects 0.000 claims abstract description 16
- 231100000419 toxicity Toxicity 0.000 claims abstract description 5
- 230000001988 toxicity Effects 0.000 claims abstract description 5
- 108091070501 miRNA Proteins 0.000 claims description 572
- 239000000090 biomarker Substances 0.000 claims description 174
- 210000001519 tissue Anatomy 0.000 claims description 115
- 210000004027 cell Anatomy 0.000 claims description 113
- 108091086416 miR-192 stem-loop Proteins 0.000 claims description 102
- 108091033773 MiR-155 Proteins 0.000 claims description 98
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 78
- 206010028980 Neoplasm Diseases 0.000 claims description 76
- 201000010099 disease Diseases 0.000 claims description 70
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 70
- 201000011510 cancer Diseases 0.000 claims description 68
- 108091023108 miR-30e stem-loop Proteins 0.000 claims description 67
- 108091027549 miR-30e-1 stem-loop Proteins 0.000 claims description 64
- 108091029213 miR-30e-2 stem-loop Proteins 0.000 claims description 64
- 210000002381 plasma Anatomy 0.000 claims description 64
- 108091028141 MiR-203 Proteins 0.000 claims description 59
- 238000012216 screening Methods 0.000 claims description 50
- 206010061218 Inflammation Diseases 0.000 claims description 43
- 108091080933 Mir-192/215 microRNA precursor Proteins 0.000 claims description 43
- 230000004054 inflammatory process Effects 0.000 claims description 43
- 108091088730 miR-215 stem-loop Proteins 0.000 claims description 43
- 108091028684 Mir-145 Proteins 0.000 claims description 42
- 108091027034 miR-148a stem-loop Proteins 0.000 claims description 39
- 210000004072 lung Anatomy 0.000 claims description 38
- 108091054642 miR-194 stem-loop Proteins 0.000 claims description 38
- 108091039994 miR-486 stem-loop Proteins 0.000 claims description 35
- 230000014509 gene expression Effects 0.000 claims description 34
- 108091028761 miR-409 stem-loop Proteins 0.000 claims description 34
- 108091028080 MiR-132 Proteins 0.000 claims description 33
- 108091093073 MiR-134 Proteins 0.000 claims description 32
- 210000002345 respiratory system Anatomy 0.000 claims description 29
- 108091060585 Mir-31 Proteins 0.000 claims description 22
- 108091079013 miR-34b Proteins 0.000 claims description 22
- 108091084018 miR-34b stem-loop Proteins 0.000 claims description 22
- 108091063470 miR-34b-1 stem-loop Proteins 0.000 claims description 22
- 108091049916 miR-34b-2 stem-loop Proteins 0.000 claims description 22
- 108091057222 miR-34b-3 stem-loop Proteins 0.000 claims description 22
- 108091092639 miR-34b-4 stem-loop Proteins 0.000 claims description 22
- 108091080995 Mir-9/mir-79 microRNA precursor family Proteins 0.000 claims description 21
- 108091084058 miR-874 stem-loop Proteins 0.000 claims description 21
- 108091047084 miR-9 stem-loop Proteins 0.000 claims description 21
- 108091023818 miR-7 stem-loop Proteins 0.000 claims description 20
- 108091062140 Mir-223 Proteins 0.000 claims description 19
- 108091070946 miR-128 stem-loop Proteins 0.000 claims description 19
- 108091032985 miR-382 Proteins 0.000 claims description 19
- 108091050135 miR-382 stem-loop Proteins 0.000 claims description 19
- -1 miR-146b-5p Proteins 0.000 claims description 18
- 108091062225 miR-323 stem-loop Proteins 0.000 claims description 18
- 108091069917 miR-491 stem-loop Proteins 0.000 claims description 16
- 108091058688 miR-141 stem-loop Proteins 0.000 claims description 15
- 230000000771 oncological effect Effects 0.000 claims description 15
- 210000002966 serum Anatomy 0.000 claims description 15
- 108091079658 miR-142-1 stem-loop Proteins 0.000 claims description 14
- 108091071830 miR-142-2 stem-loop Proteins 0.000 claims description 14
- 108091031103 miR-181a stem-loop Proteins 0.000 claims description 14
- 108091046591 miR-181a-4 stem-loop Proteins 0.000 claims description 14
- 108091049627 miR-181a-5 stem-loop Proteins 0.000 claims description 14
- 108091036633 miR-370 stem-loop Proteins 0.000 claims description 14
- 210000002700 urine Anatomy 0.000 claims description 14
- 230000002829 reductive effect Effects 0.000 claims description 13
- 206010021143 Hypoxia Diseases 0.000 claims description 11
- 108091028076 Mir-127 Proteins 0.000 claims description 11
- 230000007954 hypoxia Effects 0.000 claims description 11
- 230000015556 catabolic process Effects 0.000 claims description 8
- 238000006731 degradation reaction Methods 0.000 claims description 8
- 108091091807 let-7a stem-loop Proteins 0.000 claims description 8
- 108091057746 let-7a-4 stem-loop Proteins 0.000 claims description 8
- 108091028376 let-7a-5 stem-loop Proteins 0.000 claims description 8
- 108091024393 let-7a-6 stem-loop Proteins 0.000 claims description 8
- 108091091174 let-7a-7 stem-loop Proteins 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 7
- 210000000653 nervous system Anatomy 0.000 claims description 7
- 210000000777 hematopoietic system Anatomy 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 210000002346 musculoskeletal system Anatomy 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 4
- 239000010839 body fluid Substances 0.000 claims description 4
- 210000000748 cardiovascular system Anatomy 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 210000000750 endocrine system Anatomy 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 4
- 230000002588 toxic effect Effects 0.000 claims description 4
- 210000002229 urogenital system Anatomy 0.000 claims description 4
- 108091061943 Mir-218 microRNA precursor family Proteins 0.000 claims description 3
- 108091064157 miR-106a stem-loop Proteins 0.000 claims description 3
- 108091091360 miR-125b stem-loop Proteins 0.000 claims description 3
- 108091040176 miR-218 stem-loop Proteins 0.000 claims description 3
- 108091007420 miR‐142 Proteins 0.000 claims description 3
- 108091062154 Mir-205 Proteins 0.000 claims 4
- 108091028049 Mir-221 microRNA Proteins 0.000 claims 4
- 108091093189 Mir-375 Proteins 0.000 claims 4
- 108091023796 miR-182 stem-loop Proteins 0.000 claims 4
- 108091074450 miR-200c stem-loop Proteins 0.000 claims 4
- 238000003757 reverse transcription PCR Methods 0.000 claims 4
- 108091007685 MIR541 Proteins 0.000 claims 2
- 108091007700 MIR543 Proteins 0.000 claims 2
- 108091034054 MiR-138 Proteins 0.000 claims 2
- 108091093082 MiR-146 Proteins 0.000 claims 2
- 108091028108 MiR-212 Proteins 0.000 claims 2
- 108091027966 Mir-137 Proteins 0.000 claims 2
- 108091027766 Mir-143 Proteins 0.000 claims 2
- 108091028232 Mir-184 Proteins 0.000 claims 2
- 108091045790 miR-106b stem-loop Proteins 0.000 claims 2
- 108091055434 miR-124a stem-loop Proteins 0.000 claims 2
- 108091082871 miR-124a-2 stem-loop Proteins 0.000 claims 2
- 108091050112 miR-124a-4 stem-loop Proteins 0.000 claims 2
- 108091054623 miR-124a-5 stem-loop Proteins 0.000 claims 2
- 108091024680 miR-124a-6 stem-loop Proteins 0.000 claims 2
- 108091024609 miR-124b stem-loop Proteins 0.000 claims 2
- 108091081188 miR-124b-1 stem-loop Proteins 0.000 claims 2
- 108091060300 miR-124b-2 stem-loop Proteins 0.000 claims 2
- 108091044988 miR-125a stem-loop Proteins 0.000 claims 2
- 108091049513 miR-125a-1 stem-loop Proteins 0.000 claims 2
- 108091040046 miR-125a-2 stem-loop Proteins 0.000 claims 2
- 108091028466 miR-130b stem-loop Proteins 0.000 claims 2
- 108091045872 miR-135 stem-loop Proteins 0.000 claims 2
- 108091026523 miR-135a stem-loop Proteins 0.000 claims 2
- 108091026375 miR-135b stem-loop Proteins 0.000 claims 2
- 108091086065 miR-135b-2 stem-loop Proteins 0.000 claims 2
- 108091047467 miR-136 stem-loop Proteins 0.000 claims 2
- 108091030496 miR-138 stem-loop Proteins 0.000 claims 2
- 108091064825 miR-181c stem-loop Proteins 0.000 claims 2
- 108091044400 miR-181c-1 stem-loop Proteins 0.000 claims 2
- 108091048818 miR-181c-2 stem-loop Proteins 0.000 claims 2
- 108091032779 miR-181c-3 stem-loop Proteins 0.000 claims 2
- 108091028751 miR-188 stem-loop Proteins 0.000 claims 2
- 108091088515 miR-197 stem-loop Proteins 0.000 claims 2
- 108091092012 miR-199b stem-loop Proteins 0.000 claims 2
- 108091059199 miR-200a stem-loop Proteins 0.000 claims 2
- 108091089775 miR-200b stem-loop Proteins 0.000 claims 2
- 108091048308 miR-210 stem-loop Proteins 0.000 claims 2
- 108091050113 miR-211 stem-loop Proteins 0.000 claims 2
- 108091053935 miR-212 stem-loop Proteins 0.000 claims 2
- 108091028397 miR-212-1 stem-loop Proteins 0.000 claims 2
- 108091028945 miR-212-2 stem-loop Proteins 0.000 claims 2
- 108091063841 miR-219 stem-loop Proteins 0.000 claims 2
- 108091061917 miR-221 stem-loop Proteins 0.000 claims 2
- 108091063489 miR-221-1 stem-loop Proteins 0.000 claims 2
- 108091055391 miR-221-2 stem-loop Proteins 0.000 claims 2
- 108091031076 miR-221-3 stem-loop Proteins 0.000 claims 2
- 108091080321 miR-222 stem-loop Proteins 0.000 claims 2
- 108091061970 miR-26a stem-loop Proteins 0.000 claims 2
- 108091083275 miR-26b stem-loop Proteins 0.000 claims 2
- 108091074796 miR-26c stem-loop Proteins 0.000 claims 2
- 108091050195 miR-302b stem-loop Proteins 0.000 claims 2
- 108091070038 miR-338 stem-loop Proteins 0.000 claims 2
- 108091057188 miR-369 stem-loop Proteins 0.000 claims 2
- 108091071616 miR-376c stem-loop Proteins 0.000 claims 2
- 108091041657 miR-381 stem-loop Proteins 0.000 claims 2
- 108091090987 miR-425 stem-loop Proteins 0.000 claims 2
- 108091059135 miR-429 stem-loop Proteins 0.000 claims 2
- 108091084055 miR-433 stem-loop Proteins 0.000 claims 2
- 108091056535 miR-455-1 stem-loop Proteins 0.000 claims 2
- 108091035982 miR-485 stem-loop Proteins 0.000 claims 2
- 108091031110 miR-539 stem-loop Proteins 0.000 claims 2
- 108091023526 miR-541 stem-loop Proteins 0.000 claims 2
- 108091076271 miR-543 stem-loop Proteins 0.000 claims 2
- 108091063911 miR-650 stem-loop Proteins 0.000 claims 2
- 108091089548 miR-656 stem-loop Proteins 0.000 claims 2
- 108091071148 miR-935 stem-loop Proteins 0.000 claims 2
- 108091024443 miRa-135-1 stem-loop Proteins 0.000 claims 2
- 238000005259 measurement Methods 0.000 abstract description 13
- 238000004364 calculation method Methods 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 149
- 238000004422 calculation algorithm Methods 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 28
- 210000004556 brain Anatomy 0.000 description 24
- 208000027866 inflammatory disease Diseases 0.000 description 24
- 206010035664 Pneumonia Diseases 0.000 description 22
- 108091091751 miR-17 stem-loop Proteins 0.000 description 22
- 108091044046 miR-17-1 stem-loop Proteins 0.000 description 22
- 108091065423 miR-17-3 stem-loop Proteins 0.000 description 22
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 22
- 210000002784 stomach Anatomy 0.000 description 22
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 22
- 210000001072 colon Anatomy 0.000 description 21
- 230000035945 sensitivity Effects 0.000 description 21
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 20
- 208000006673 asthma Diseases 0.000 description 20
- 238000010606 normalization Methods 0.000 description 19
- 238000012545 processing Methods 0.000 description 19
- 208000011231 Crohn disease Diseases 0.000 description 18
- 108091028066 Mir-126 Proteins 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 17
- 208000024827 Alzheimer disease Diseases 0.000 description 17
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 17
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 108020004999 messenger RNA Proteins 0.000 description 17
- 210000000664 rectum Anatomy 0.000 description 17
- 230000000391 smoking effect Effects 0.000 description 17
- 210000003238 esophagus Anatomy 0.000 description 16
- 238000000746 purification Methods 0.000 description 15
- 238000003748 differential diagnosis Methods 0.000 description 14
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 13
- 208000005718 Stomach Neoplasms Diseases 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 238000012549 training Methods 0.000 description 12
- 208000018522 Gastrointestinal disease Diseases 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 208000029742 colonic neoplasm Diseases 0.000 description 11
- 230000036470 plasma concentration Effects 0.000 description 11
- 230000028327 secretion Effects 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 108091007427 let-7g Proteins 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 108020004707 nucleic acids Proteins 0.000 description 9
- 102000039446 nucleic acids Human genes 0.000 description 9
- 150000007523 nucleic acids Chemical class 0.000 description 9
- 238000003752 polymerase chain reaction Methods 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 238000011160 research Methods 0.000 description 9
- 208000019693 Lung disease Diseases 0.000 description 8
- 108091007772 MIRLET7C Proteins 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 206010017758 gastric cancer Diseases 0.000 description 8
- 201000011549 stomach cancer Diseases 0.000 description 8
- 206010012289 Dementia Diseases 0.000 description 7
- 208000015634 Rectal Neoplasms Diseases 0.000 description 7
- 238000004590 computer program Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 210000000225 synapse Anatomy 0.000 description 7
- 230000014616 translation Effects 0.000 description 7
- 208000005623 Carcinogenesis Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 208000037273 Pathologic Processes Diseases 0.000 description 6
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 6
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 6
- 230000036952 cancer formation Effects 0.000 description 6
- 231100000504 carcinogenesis Toxicity 0.000 description 6
- 238000013399 early diagnosis Methods 0.000 description 6
- 208000015122 neurodegenerative disease Diseases 0.000 description 6
- 230000009054 pathological process Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000000377 silicon dioxide Substances 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 238000007635 classification algorithm Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 210000001723 extracellular space Anatomy 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000004807 localization Effects 0.000 description 5
- 108091047596 miR-1559 stem-loop Proteins 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 210000000496 pancreas Anatomy 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 201000000498 stomach carcinoma Diseases 0.000 description 5
- 238000003860 storage Methods 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 230000004888 barrier function Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 108091028606 miR-1 stem-loop Proteins 0.000 description 4
- 108091037473 miR-103 stem-loop Proteins 0.000 description 4
- 108091035155 miR-10a stem-loop Proteins 0.000 description 4
- 210000002241 neurite Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 238000013515 script Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000003932 urinary bladder Anatomy 0.000 description 4
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 3
- 208000030619 Crohn disease of the esophagus Diseases 0.000 description 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000003050 axon Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000001787 dendrite Anatomy 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 210000002249 digestive system Anatomy 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 108091023663 let-7 stem-loop Proteins 0.000 description 3
- 108091063478 let-7-1 stem-loop Proteins 0.000 description 3
- 108091049777 let-7-2 stem-loop Proteins 0.000 description 3
- 108091007423 let-7b Proteins 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000007477 logistic regression Methods 0.000 description 3
- 238000007726 management method Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 108091031326 miR-15b stem-loop Proteins 0.000 description 3
- 238000007481 next generation sequencing Methods 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 241001559589 Cullen Species 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108091030146 MiRBase Proteins 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 208000035977 Rare disease Diseases 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108020003224 Small Nucleolar RNA Proteins 0.000 description 2
- 102000042773 Small Nucleolar RNA Human genes 0.000 description 2
- 238000012167 Small RNA sequencing Methods 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000004727 amygdala Anatomy 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000001638 cerebellum Anatomy 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000007901 in situ hybridization Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 150000002605 large molecules Chemical class 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108091064282 miR-125 stem-loop Proteins 0.000 description 2
- 108091037066 miR-125-1 stem-loop Proteins 0.000 description 2
- 108091062107 miR-125-2 stem-loop Proteins 0.000 description 2
- 108091079767 miR-125-3 stem-loop Proteins 0.000 description 2
- 108091039164 miR-147b stem-loop Proteins 0.000 description 2
- 108091041686 miR-155-2 stem-loop Proteins 0.000 description 2
- 108091027943 miR-16 stem-loop Proteins 0.000 description 2
- 108091051187 miR-486b stem-loop Proteins 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000016273 neuron death Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 210000003101 oviduct Anatomy 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 230000013878 renal filtration Effects 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 239000003161 ribonuclease inhibitor Substances 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000012706 support-vector machine Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- DQJCHOQLCLEDLL-UHFFFAOYSA-N tricyclazole Chemical compound CC1=CC=CC2=C1N1C=NN=C1S2 DQJCHOQLCLEDLL-UHFFFAOYSA-N 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000219195 Arabidopsis thaliana Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 206010049119 Emotional distress Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091027974 Mature messenger RNA Proteins 0.000 description 1
- 108091007780 MiR-122 Proteins 0.000 description 1
- 108091062170 Mir-22 Proteins 0.000 description 1
- 108091027559 Mir-96 microRNA Proteins 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 102000043141 Nuclear RNA Human genes 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 241001482576 Saiga Species 0.000 description 1
- 238000003646 Spearman's rank correlation coefficient Methods 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000012863 analytical testing Methods 0.000 description 1
- 238000013103 analytical ultracentrifugation Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008335 axon cargo transport Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000138 intercalating agent Substances 0.000 description 1
- 235000020061 kirsch Nutrition 0.000 description 1
- 108091042844 let-7i stem-loop Proteins 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 108091064399 miR-10b stem-loop Proteins 0.000 description 1
- 108091051828 miR-122 stem-loop Proteins 0.000 description 1
- 108091026501 miR-122a stem-loop Proteins 0.000 description 1
- 108091056924 miR-124 stem-loop Proteins 0.000 description 1
- 108091043184 miR-1246 stem-loop Proteins 0.000 description 1
- 108091089860 miR-148 stem-loop Proteins 0.000 description 1
- 108091029500 miR-183 stem-loop Proteins 0.000 description 1
- 108091091977 miR-1929 stem-loop Proteins 0.000 description 1
- 108091062762 miR-21 stem-loop Proteins 0.000 description 1
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 1
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 1
- 108091062345 miR-270 stem-loop Proteins 0.000 description 1
- 108091023968 miR-330 stem-loop Proteins 0.000 description 1
- 108091055145 miR-342 stem-loop Proteins 0.000 description 1
- 108091090954 miR-3823 stem-loop Proteins 0.000 description 1
- 108091052738 miR-486-1 stem-loop Proteins 0.000 description 1
- 108091030654 miR-486-2 stem-loop Proteins 0.000 description 1
- 108091062136 miR-939 stem-loop Proteins 0.000 description 1
- 108091086713 miR-96 stem-loop Proteins 0.000 description 1
- 108091070961 miR-96-3 stem-loop Proteins 0.000 description 1
- 108091076732 miR-99a stem-loop Proteins 0.000 description 1
- 108091064318 miR-99a-1 stem-loop Proteins 0.000 description 1
- 108091086202 miR-99a-2 stem-loop Proteins 0.000 description 1
- 108091090735 miR159 stem-loop Proteins 0.000 description 1
- 108091044835 miR159a stem-loop Proteins 0.000 description 1
- 108091029387 miR160e stem-loop Proteins 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004457 myocytus nodalis Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 238000009595 pap smear Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000003976 synaptic dysfunction Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 238000013024 troubleshooting Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161476591P | 2011-04-18 | 2011-04-18 | |
| US61/476,591 | 2011-04-18 | ||
| US201161478766P | 2011-04-25 | 2011-04-25 | |
| US61/478,766 | 2011-04-25 | ||
| US201161546431P | 2011-10-12 | 2011-10-12 | |
| US61/546,431 | 2011-10-12 | ||
| PCT/US2012/034098 WO2012145409A1 (en) | 2011-04-18 | 2012-04-18 | miRNA-BASED UNIVERSAL SCREENING TEST (UST) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2013146856A RU2013146856A (ru) | 2015-05-27 |
| RU2626540C2 true RU2626540C2 (ru) | 2017-07-28 |
Family
ID=47041896
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013146856A RU2626540C2 (ru) | 2011-04-18 | 2012-04-18 | Способы обнаружения патологических изменений в органе или системе органов |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US9803242B2 (enExample) |
| EP (4) | EP2699666B1 (enExample) |
| JP (3) | JP6211511B2 (enExample) |
| CN (3) | CN103620057B (enExample) |
| AU (2) | AU2012245580B2 (enExample) |
| CA (2) | CA2833375A1 (enExample) |
| ES (1) | ES2630602T3 (enExample) |
| RU (1) | RU2626540C2 (enExample) |
| WO (2) | WO2012145363A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2677280C1 (ru) * | 2018-05-17 | 2019-01-16 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики многососудистого атеросклеротического поражения коронарных артерий у больных ишемической болезнью сердца при абдоминальном ожирении |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6211511B2 (ja) | 2011-04-18 | 2017-10-11 | ディアミール, エルエルシーDiamir, Llc | ｍｉＲＮＡに基づくユニバーサルスクリーニングテスト（ＵＳＴ） |
| US20140087964A1 (en) * | 2012-09-24 | 2014-03-27 | University Of Virginia Patent Foundation | Compositions and methods for detecting aberrant regulation, expression, and levels of hgh |
| US20140100124A1 (en) * | 2012-10-04 | 2014-04-10 | Asuragen, Inc. | Diagnostic mirnas for differential diagnosis of incidental pancreatic cystic lesions |
| CN104903468B (zh) | 2012-11-16 | 2019-04-23 | 萨尔大学 | 用于帕金森氏病的新诊断MiRNA标志物 |
| EP2733219B1 (en) | 2012-11-16 | 2017-09-20 | Siemens Aktiengesellschaft | Diagnostic miRNA markers for Alzheimer |
| EP2733220B1 (en) | 2012-11-16 | 2017-10-18 | Siemens Aktiengesellschaft | Novel miRNA as a diagnostic marker for Alzheimer's Disease |
| JP2014128249A (ja) * | 2012-12-28 | 2014-07-10 | Hokkaido Univ | 神経変性疾患の検査と治療に対するｍｉＲＮＡ又はその標的遺伝子の利用 |
| CN103805693B (zh) * | 2013-10-29 | 2017-01-11 | 宁夏医科大学 | 微小分子RNA-508-5p作为抗肿瘤标志物的用途 |
| WO2015073972A1 (en) | 2013-11-18 | 2015-05-21 | Diamir, Llc | METHODS OF USING mIRNAs FROM BODILY FLUIDS FOR DETECTION AND MONITORING OF PARKINSON'S DISEASE (PD) |
| CA2939343A1 (en) * | 2014-02-18 | 2015-08-27 | Baylor Research Institute | Mir-320e and colorectal cancer |
| EP4560026A3 (en) * | 2014-04-10 | 2025-08-27 | The Trustees of the University of Pennsylvania | Use of micro-ribonucleic acid (mirna) to diagnose transplant rejection and tolerance of immunosuppression therapy |
| CN103937888B (zh) * | 2014-04-14 | 2016-08-17 | 上海交通大学 | 鉴别胃癌的血浆microRNA标志物的筛选与应用 |
| WO2015164431A2 (en) * | 2014-04-22 | 2015-10-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods, processes, devices and kits for the measurement of post traumatic stress disorder microrna markers |
| WO2015181825A1 (en) * | 2014-05-28 | 2015-12-03 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Methods of glucocorticoid therapy and determining responsiveness thereof |
| CN111910002B (zh) * | 2014-06-18 | 2024-04-12 | 东丽株式会社 | 食道癌的检测试剂盒或装置以及检测方法 |
| WO2016138287A1 (en) * | 2015-02-25 | 2016-09-01 | Washington University | METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAs |
| AU2016267392B2 (en) * | 2015-05-28 | 2021-12-09 | Immunexpress Pty Ltd | Validating biomarker measurement |
| RU2718534C2 (ru) | 2015-06-05 | 2020-04-08 | Мираджен Терапьютикс, Инк. | Ингибиторы mir-155 для лечения кожной t-клеточной лимфомы (ctcl) |
| CN104940954B (zh) * | 2015-06-23 | 2017-12-26 | 同济大学 | MicroRNA‑7在制备抗胶质化药物中的应用 |
| CN108026570A (zh) * | 2015-09-11 | 2018-05-11 | 康宁股份有限公司 | 从血液样品中纯化核酸的组合物和方法 |
| ES2734678T3 (es) * | 2015-12-22 | 2019-12-11 | Siemens Ag | Firmas específicas en enfermedad de alzheimer por perfiles de miarn multicéntricos |
| US10975436B2 (en) | 2016-01-05 | 2021-04-13 | Diamir, Llc | Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders |
| WO2017120285A1 (en) * | 2016-01-05 | 2017-07-13 | Diamir, Llc | METHODS OF USING miRNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEVELOPMENTAL DISORDERS |
| US11149313B2 (en) | 2016-03-21 | 2021-10-19 | Diamir, Llc | Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases |
| WO2017186719A1 (en) * | 2016-04-25 | 2017-11-02 | Instytut Biologii Doswiadczalnej Im. Marcelego Nenckiego Polska Akademia Nauk | Microrna biomarkers in blood for diagnosis of alzheimer's disease |
| BR112019005172A2 (pt) * | 2016-09-16 | 2019-07-02 | Dyax Corp. | método e kit para analisar uma amostra |
| CN106544435A (zh) * | 2016-09-30 | 2017-03-29 | 河北医科大学第医院 | 检测miR‑206所需逆转录引物对在制备预测试剂盒中的应用 |
| GB201616691D0 (en) * | 2016-09-30 | 2016-11-16 | King S College London | Assay |
| SG10201709799SA (en) * | 2016-11-29 | 2018-06-28 | Helios Bioelectronics Inc | Method for quantitatively profiling nucleic acids |
| US20190345551A1 (en) * | 2016-12-28 | 2019-11-14 | National University Corporation Kumamoto University | METHOD FOR DETECTING MITOCHONDRIAL tRAN MODIFICATION |
| WO2018139759A1 (ko) * | 2017-01-26 | 2018-08-02 | 주식회사 바이오오케스트라 | 마이크로 rna를 이용한 알츠하이머병 진단방법 |
| AU2018300159A1 (en) * | 2017-07-12 | 2020-02-06 | Texas Tech University System | MicroRNA-455-3p as a peripheral biomarker for Alzheimer's disease |
| US10781487B2 (en) | 2017-07-24 | 2020-09-22 | Diamir, Llc | miRNA-based methods for detecting and monitoring aging |
| KR101830583B1 (ko) * | 2017-08-11 | 2018-02-20 | 주식회사 인피니트헬스케어 | Ｗｓｉ 스트리밍 방법 |
| US11723579B2 (en) | 2017-09-19 | 2023-08-15 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement |
| CN107811609B (zh) * | 2017-09-22 | 2020-06-09 | 中国医学科学院北京协和医院 | 一种脑老化评估系统 |
| US11377699B2 (en) * | 2017-11-30 | 2022-07-05 | Provincial Health Services Authority | Methods for evaluating head and neck cancers |
| US11717686B2 (en) | 2017-12-04 | 2023-08-08 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to facilitate learning and performance |
| US12280219B2 (en) | 2017-12-31 | 2025-04-22 | NeuroLight, Inc. | Method and apparatus for neuroenhancement to enhance emotional response |
| US11478603B2 (en) | 2017-12-31 | 2022-10-25 | Neuroenhancement Lab, LLC | Method and apparatus for neuroenhancement to enhance emotional response |
| EP3754019B1 (en) | 2018-02-13 | 2024-01-31 | Toray Industries, Inc. | Use of a kit or device and method for detecting dementia |
| US11364361B2 (en) | 2018-04-20 | 2022-06-21 | Neuroenhancement Lab, LLC | System and method for inducing sleep by transplanting mental states |
| US11332789B2 (en) | 2018-05-21 | 2022-05-17 | Temple University-Of The Commonwealth System Of Higher Education | Compositions and methods for diagnosing and treating hyperlipidemia-related diseases |
| EP3807422B1 (en) | 2018-06-15 | 2025-12-03 | Universitat Autònoma de Barcelona | Circulating mirnas as biomarkers for diagnosis of mild cognitive impairment and alzheimer´s disease |
| WO2020056418A1 (en) | 2018-09-14 | 2020-03-19 | Neuroenhancement Lab, LLC | System and method of improving sleep |
| CN109055541B (zh) * | 2018-09-26 | 2020-08-28 | 上海市精神卫生中心（上海市心理咨询培训中心） | Ad所致mci诊断标志物及其应用 |
| US11786694B2 (en) | 2019-05-24 | 2023-10-17 | NeuroLight, Inc. | Device, method, and app for facilitating sleep |
| US20230256119A1 (en) * | 2019-06-17 | 2023-08-17 | Biorchestra Co., Ltd. | Compositions and methods for preparing an alzheimer's disease animal model using microrna |
| US11198908B2 (en) | 2019-06-17 | 2021-12-14 | Biorchestra Co., Ltd. | Method for diagnosis of Alzheimer's disease using microRNA |
| CA3175419A1 (en) * | 2020-04-23 | 2021-10-28 | Jin-Hyeob RYU | Diagnostic methods using mir-485-3p expression |
| US20220073992A1 (en) * | 2020-11-24 | 2022-03-10 | Hossein Abdul Tehrani Abdul Tehrani | Diagnosis of chronic kidney disease (ckd) and its subgroups |
| CN112562867A (zh) * | 2021-02-22 | 2021-03-26 | 天津迈德新医药科技有限公司 | 一种预测极早期hiv感染风险的装置、存储介质和电子装置 |
| CN112980954B (zh) * | 2021-03-03 | 2022-02-25 | 首都医科大学宣武医院 | 一种预测神经退行性疾病风险的试剂盒及其用途 |
| CN115976194A (zh) * | 2022-12-12 | 2023-04-18 | 天津市肿瘤医院空港医院 | 一种基于外泌体微小rna的神经系统疾病诊断方法 |
| WO2025089057A1 (ja) * | 2023-10-24 | 2025-05-01 | アークレイ株式会社 | スモールｒｎａ測定用血液試料の調製方法及び保存方法、スモールｒｎａの発現量の測定方法、疾患の判定方法、検査方法、モデルの生成方法、検査装置、検査システム、検査プログラム、並びに記録媒体 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2367959C1 (ru) * | 2008-03-05 | 2009-09-20 | Государственное образовательное учреждение высшего профессионального образования "Омский государственный университет им. Ф.М. Достоевского" | Способ лабораторной диагностики заболеваний ротовой полости по элементному составу слюны |
| WO2009120877A2 (en) * | 2008-03-26 | 2009-10-01 | The Johns Hopkins University | Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases |
| WO2009133915A1 (ja) * | 2008-04-30 | 2009-11-05 | 日本電気株式会社 | 癌マーカー、それを用いた癌の評価方法および評価試薬 |
| WO2010117829A2 (en) * | 2009-03-31 | 2010-10-14 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome |
| WO2011015720A1 (fr) * | 2009-07-29 | 2011-02-10 | Centre National De La Recherche Scientifique | Utilisation de microarn pour le traitement de pathologies liées à un dysfonctionnement des cils des cellules épithéliales multiciliées |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5071A (en) | 1847-04-17 | George page | ||
| US743A (en) | 1838-05-17 | Improvement in plows | ||
| FR2552909B1 (fr) | 1983-09-30 | 1985-11-08 | Thomson Csf | Appareil indicateur cartographique de relief et son u tilisation pour la navigation aerienne |
| US4829304A (en) | 1986-05-20 | 1989-05-09 | Harris Corp. | Map-aided navigation system employing TERCOM-SITAN signal processing |
| KR940002799B1 (ko) | 1986-07-28 | 1994-04-02 | 가부시끼가이샤 도요다지도오쇽기 세이사꾸쇼 | 보텀 드래프트 로울러의 청소장치 |
| US4939663A (en) | 1988-04-04 | 1990-07-03 | Harris Corporation | Elevation map-referenced mechanism for updating vehicle navigation system estimates |
| EP0381178A1 (en) | 1989-02-02 | 1990-08-08 | Honeywell Inc. | Method and apparatus for aircraft navigation |
| US5071743A (en) | 1989-10-27 | 1991-12-10 | Her Majesty The Queen In Right Of Canada, As Represented By The National Research Council Of Canada | Process for conducting site-directed mutagenesis |
| JP3442774B2 (ja) | 1991-07-01 | 2003-09-02 | バーレックス ラボラトリーズ，インコーポレイティド | 新規な突然変異誘発法および組成物 |
| US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| US6242222B1 (en) | 1996-06-07 | 2001-06-05 | Massachusetts Institute Of Technology | Programmed sequential mutagenesis |
| US5780270A (en) | 1996-07-17 | 1998-07-14 | Promega Corporation | Site-specific mutagenesis and mutant selection utilizing antibiotic-resistant markers encoding gene products having altered substrate specificity |
| EP2290071B1 (en) | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| EP2314688B1 (en) * | 2004-11-12 | 2014-07-16 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
| EP1966390A1 (en) | 2005-12-29 | 2008-09-10 | Exiqon A/S | Detection of tissue origin of cancer |
| EP2487260B1 (en) * | 2006-01-05 | 2015-07-08 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis and treatment of solid cancers |
| WO2007100911A2 (en) | 2006-02-28 | 2007-09-07 | University Of Louisville Research Foundation | Detecting fetal chromosomal abnormalities using tandem single nucleotide polymorphisms |
| AU2007299828C1 (en) * | 2006-09-19 | 2014-07-17 | Interpace Diagnostics, Llc | MicroRNAs differentially expressed in pancreatic diseases and uses thereof |
| EP2081442B1 (en) | 2006-10-10 | 2016-08-10 | TrovaGene, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
| US8586725B2 (en) * | 2007-02-16 | 2013-11-19 | The Johns Hopkins University | MicroRNAome |
| US20100167948A1 (en) | 2007-05-22 | 2010-07-01 | The Brigham And Women's Hospital, Inc. | MicroRNA Expression Profiling of Cerebrospinal Fluid |
| US20090004668A1 (en) | 2007-06-22 | 2009-01-01 | The Board Of Trustees Of The Leland Stanford Junior University | Pre-miRNA loop-modulated target regulation |
| WO2009009457A1 (en) | 2007-07-06 | 2009-01-15 | University Of Louisville Research Foundation, Inc. | Alzheimer's disease-specific micro-rna microarray and related methods |
| KR20100049079A (ko) | 2007-07-18 | 2010-05-11 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 인간의 정상 심장과 기능부진 심장에서 마이크로 ｒｎａ의 차등 발현 |
| CA2676113C (en) | 2007-07-25 | 2014-07-08 | University Of Louisville Research Foundation, Inc. | Exosome-associated microrna as a diagnostic marker |
| CN101861399B (zh) | 2007-08-22 | 2015-11-25 | 特罗瓦基因公司 | 使用miRNA检测体内细胞死亡情况的方法 |
| US7653509B2 (en) | 2007-08-29 | 2010-01-26 | Verity Software House | Probability state models |
| US7993831B2 (en) * | 2007-09-14 | 2011-08-09 | Asuragen, Inc. | Methods of normalization in microRNA detection assays |
| US8455199B2 (en) | 2007-09-14 | 2013-06-04 | The Ohio State University Research Foundation | MicroRNA expression in human peripheral blood microvesicles and uses thereof |
| US20100323357A1 (en) | 2007-11-30 | 2010-12-23 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer |
| EP2604704B1 (en) | 2008-02-01 | 2018-10-03 | The General Hospital Corporation | Use of microvesicles in diagnosis and prognosis of brain tumor |
| CA2716906A1 (en) * | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | Microrna-based methods and compositions for the diagnosis, prognosis and treatment of gastric cancer |
| US20110160285A1 (en) | 2008-03-13 | 2011-06-30 | The Regents Of The University Of Colorado | Identification of mirna profiles that are diagnostic of hypertrophic cardiomyopathy |
| WO2009132273A2 (en) | 2008-04-25 | 2009-10-29 | Merck & Co., Inc. | Microrna biomarkers of tissue injury |
| US20110160290A1 (en) | 2008-05-21 | 2011-06-30 | Muneesh Tewari | Use of extracellular rna to measure disease |
| US20100167937A1 (en) | 2008-07-08 | 2010-07-01 | Power3 Medical Products, Inc. | Multiple forms of Alzheimer's disease based on differences in concentrations of protein biomarkers in blood serum |
| WO2010054386A2 (en) | 2008-11-10 | 2010-05-14 | Battelle Memorial Institute | Methods, compositions, and devices utilizing microrna to determine physiological conditions |
| EP3181705A1 (en) * | 2008-11-12 | 2017-06-21 | Caris Life Sciences Switzerland Holdings GmbH | Methods and systems of using exosomes for determining phenotypes |
| US20110086348A1 (en) | 2009-02-19 | 2011-04-14 | The Cleveland Clinic Foundation | Method for assessing heart disease |
| US20100227908A1 (en) * | 2009-03-05 | 2010-09-09 | Newcastle Innovation Limited | Diagnostic, prognostic and treatment methods |
| AU2010237191A1 (en) | 2009-04-07 | 2011-11-03 | Velin-Pharma A/S | Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system |
| CA2757711A1 (en) | 2009-04-14 | 2010-10-21 | Merck Sharp & Dohme Corp. | Microrna as a biomarker of pancreatic islet beta-cell engagement |
| JP5898065B2 (ja) | 2009-05-20 | 2016-04-06 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニーＥ．Ｉ．Ｄｕ Ｐｏｎｔ Ｄｅ Ｎｅｍｏｕｒｓ Ａｎｄ Ｃｏｍｐａｎｙ | シリコンウエハの前面上にグリッド電極を形成する方法 |
| US8735074B2 (en) | 2009-08-28 | 2014-05-27 | Asuragen, Inc. | MiRNA biomarkers of lung disease |
| EP3118334A1 (en) | 2009-11-04 | 2017-01-18 | DiamiR, LLC | Methods of using small rna from bodily fluids for diagnosis and monitoring of neurodegenerative diseases |
| US8592151B2 (en) * | 2009-11-17 | 2013-11-26 | Musc Foundation For Research Development | Assessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids |
| CN101942502B (zh) | 2009-12-24 | 2014-09-17 | 北京命码生科科技有限公司 | 胰腺癌标记物及其检测方法、试剂盒和生物芯片 |
| EP2865765B1 (en) | 2010-04-20 | 2016-08-17 | Hummingbird Diagnostics GmbH | Complex miRNA sets as novel biomarkers for an acute coronary syndrome |
| EP2619576B1 (en) | 2010-09-24 | 2020-06-10 | Niels Grabe | Means and methods for the prediction of treatment response of a cancer patient |
| CN101962685B (zh) | 2010-11-11 | 2012-09-19 | 江苏省疾病预防控制中心 | 一种基于液相芯片检测微小核糖核酸的方法 |
| JP6211511B2 (ja) | 2011-04-18 | 2017-10-11 | ディアミール, エルエルシーDiamir, Llc | ｍｉＲＮＡに基づくユニバーサルスクリーニングテスト（ＵＳＴ） |
| US9790554B2 (en) | 2011-08-19 | 2017-10-17 | Hummingbird Diagnostics Gmbh | Complex sets of miRNAs as non-invasive biomarkers for kidney cancer |
| US20140302068A1 (en) | 2011-09-09 | 2014-10-09 | The Regents Of The University Of Colorado | MicroRNA Biomarkers for Diagnosing Parkinson's Disease |
| US9447471B2 (en) | 2011-12-29 | 2016-09-20 | Quest Diagnostics Investments Incorporated | Microrna profiling for diagnosis of dysplastic nevi and melanoma |
| US9540692B2 (en) | 2012-07-25 | 2017-01-10 | Rush University Medical Center | MiRNAs as novel therapeutic targets and diagnostic biomarkers for parkinsons disease |
| US9809857B2 (en) | 2013-02-28 | 2017-11-07 | Washington University | Methods and signatures for oropharyngeal cancer prognosis |
| WO2015073972A1 (en) | 2013-11-18 | 2015-05-21 | Diamir, Llc | METHODS OF USING mIRNAs FROM BODILY FLUIDS FOR DETECTION AND MONITORING OF PARKINSON'S DISEASE (PD) |
| US9605315B2 (en) | 2014-03-26 | 2017-03-28 | The University Of Montana | Detection of traumatic brain injury |
| US9708667B2 (en) | 2014-05-13 | 2017-07-18 | Rosetta Genomics, Ltd. | MiRNA expression signature in the classification of thyroid tumors |
| WO2017120285A1 (en) | 2016-01-05 | 2017-07-13 | Diamir, Llc | METHODS OF USING miRNA FROM BODILY FLUIDS FOR DIAGNOSIS AND MONITORING OF NEURODEVELOPMENTAL DISORDERS |
| US11149313B2 (en) | 2016-03-21 | 2021-10-19 | Diamir, Llc | Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases |
| US9933440B2 (en) | 2016-05-31 | 2018-04-03 | Edward J. Goetzl | Drug efficacy test method for dementias utilizing astrocyte-derived exosomes |
-
2012
- 2012-04-18 JP JP2014506516A patent/JP6211511B2/ja active Active
- 2012-04-18 CN CN201280030048.6A patent/CN103620057B/zh active Active
- 2012-04-18 RU RU2013146856A patent/RU2626540C2/ru active
- 2012-04-18 US US14/112,684 patent/US9803242B2/en active Active
- 2012-04-18 EP EP12774179.1A patent/EP2699666B1/en active Active
- 2012-04-18 CA CA2833375A patent/CA2833375A1/en active Pending
- 2012-04-18 WO PCT/US2012/034025 patent/WO2012145363A1/en not_active Ceased
- 2012-04-18 EP EP16192259.6A patent/EP3133147B1/en active Active
- 2012-04-18 EP EP17207859.4A patent/EP3327145A1/en not_active Withdrawn
- 2012-04-18 US US14/112,765 patent/US9556487B2/en active Active
- 2012-04-18 CN CN201280030033.XA patent/CN103620019B/zh active Active
- 2012-04-18 JP JP2014506501A patent/JP6021893B2/ja active Active
- 2012-04-18 AU AU2012245580A patent/AU2012245580B2/en active Active
- 2012-04-18 CN CN201610344816.5A patent/CN105861712B/zh active Active
- 2012-04-18 EP EP12773705.4A patent/EP2699697B1/en active Active
- 2012-04-18 WO PCT/US2012/034098 patent/WO2012145409A1/en not_active Ceased
- 2012-04-18 AU AU2012245628A patent/AU2012245628B2/en active Active
- 2012-04-18 ES ES12774179.1T patent/ES2630602T3/es active Active
- 2012-04-18 CA CA2833389A patent/CA2833389C/en active Active
-
2016
- 2016-12-23 US US15/390,110 patent/US10246747B2/en active Active
-
2017
- 2017-05-26 US US15/606,747 patent/US10472681B2/en active Active
- 2017-09-12 JP JP2017174778A patent/JP2018027089A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2367959C1 (ru) * | 2008-03-05 | 2009-09-20 | Государственное образовательное учреждение высшего профессионального образования "Омский государственный университет им. Ф.М. Достоевского" | Способ лабораторной диагностики заболеваний ротовой полости по элементному составу слюны |
| WO2009120877A2 (en) * | 2008-03-26 | 2009-10-01 | The Johns Hopkins University | Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases |
| WO2009133915A1 (ja) * | 2008-04-30 | 2009-11-05 | 日本電気株式会社 | 癌マーカー、それを用いた癌の評価方法および評価試薬 |
| WO2010117829A2 (en) * | 2009-03-31 | 2010-10-14 | The United States Of America As Represented By The Secretary Department Of Health And Human Services | Differentially expressed micrornas as biomarkers for the diagnosis and treatment of sjögren's syndrome |
| WO2011015720A1 (fr) * | 2009-07-29 | 2011-02-10 | Centre National De La Recherche Scientifique | Utilisation de microarn pour le traitement de pathologies liées à un dysfonctionnement des cils des cellules épithéliales multiciliées |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2677280C1 (ru) * | 2018-05-17 | 2019-01-16 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики многососудистого атеросклеротического поражения коронарных артерий у больных ишемической болезнью сердца при абдоминальном ожирении |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2626540C2 (ru) | Способы обнаружения патологических изменений в органе или системе органов | |
| US20250122579A1 (en) | Microrna assay for detection and management of pancreatic cancer precursors | |
| Kang et al. | Identification of circulating miRNA biomarkers based on global quantitative real-time PCR profiling | |
| Courts et al. | Specific micro‐RNA signatures for the detection of saliva and blood in forensic body‐fluid identification | |
| Wu et al. | Next‐generation sequencing of microRNAs for breast cancer detection | |
| Guerau-de-Arellano et al. | miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing | |
| US20110160290A1 (en) | Use of extracellular rna to measure disease | |
| US20140243240A1 (en) | microRNA EXPRESSION PROFILING OF THYROID CANCER | |
| JP2011501966A (ja) | 結腸直腸癌監視のためのプロセス | |
| Hrustincova et al. | Circulating microRNAs: methodological aspects in detection of these biomarkers | |
| WO2011012074A1 (zh) | 肝癌检测标记物及其检测方法、试剂盒和生物芯片 | |
| Ardila-Molano et al. | Circulating microRNAs as potential cancer biomarkers | |
| CN100999765A (zh) | 以微小核糖核酸的变化鉴定结肠癌化程度的生物芯片 | |
| WO2014093504A1 (en) | Microrna biomarkers for graft versus host disease | |
| Li et al. | A comprehensive evaluation of differentially expressed mRNAs and lncRNAs in cystitis glandularis with gene ontology, KEGG pathway, and ceRNA network analysis | |
| Braicu et al. | Mirna expression assays | |
| Penman et al. | MicroRNA expression as an indicator of tissue toxicity | |
| Vlassenbroek | microRNAs as potential biomarkers for canine thyroid tumors | |
| Li et al. | Circulating miRNAs Increasing the Risk of Cancer | |
| Yang et al. | Cell‐free microRNAs as Biomarkers in Human Diseases |